Immunohistochemistry (IHC) Market Report 2026

Immunohistochemistry (IHC) Market Overview

• Immunohistochemistry (IHC) market size has reached to $2.76 billion in 2025 • Expected to grow to $4.47 billion in 2030 at a compound annual growth rate (CAGR) of 10.1% • Growth Driver: Rising Demand For Personalized Medicines Drives Growth In Immunohistochemistry (IHC) Market • Market Trend: Technological Advancements Propel Innovation In Immunohistochemistry (IHC) Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Immunohistochemistry (IHC) Market?

Immunohistochemistry (IHC) is the technique in diagnosis that uses antibody-antigen interaction to locate particular proteins and antigens in the tissue section. This interaction is visualized using chromogenic detection using enzyme-substrate or fluorescent detection using fluorescent dye. The main immunohistochemistry (IHC) products include antibodies, equipment, reagents and kits. Antibodies refer to protective proteins produced by the immune system to destroy and eliminate antigens harmful to the immune system. The antibodies are used in detecting the specific location of proteins or antigens in diagnosis. The different applications of include diagnostics, drug testing and others, which are used by end-users including hospitals and diagnostic laboratories, research institutes and others.

What Is The Immunohistochemistry (IHC) Market Growth Forecast?

The immunohistochemistry (ihc) market size is expected to see rapid growth in the next few years. It will grow to $4.47 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, rising adoption of ai-enabled pathology analysis, expansion of biomarker-driven drug development, growing use of multiplex tissue profiling, increasing investments in advanced pathology infrastructure. Major trends in the forecast period include increasing adoption of automated ihc staining systems, rising use of multiplex ihc techniques, growing integration of digital pathology platforms, expansion of companion diagnostic applications, enhanced focus on high-specificity antibodies.

Global Immunohistochemistry (IHC) Market Segmentation

1) By Product: Antibodies, Equipment, Reagents, Kits 2) By Applications: Diagnostics, Drug Testing, Other Applications 3) By End-Users: Hospitals And Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By Antibodies: Primary Antibodies, Secondary Antibodies, Conjugated Antibodies 2) By Equipment: IHC Staining Systems, Slide Scanners, Microscopes 3) By Reagents: Detection Reagents, Blocking Reagents, Mounting Media 4) By Kits: Pre-prepared IHC Kits, Multiplex IHC Kits, Specialty Kits

What Is The Driver Of The Immunohistochemistry (IHC) Market?

Growing demand for personalized medicines is expected to propel the growth of the immunohistochemistry (IHC) market going forward. Personalized medicine is a medical approach that involves tailoring medical decisions, practices, interventions, and products to the individual patient based on their unique genetic, environmental, and lifestyle characteristics. Immunohistochemistry (IHC) plays a significant role in personalized medicine as it is used to detect the presence of specific protein markers that can assist with accurate tumor classification and diagnosis. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit research organization, personalised medicines accounted for more than one-third of new approvals by the US Food and Drug Administration in 2023. In the same year, the FDA approved 16 new personalised treatments for rare-disease patients, up from 6 in 2022. Therefore, growing demand for personalized medicines is driving the growth of the immunohistochemistry (IHC) industry.

Key Players In The Global Immunohistochemistry (IHC) Market

Major companies operating in the immunohistochemistry (ihc) market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., PHC Holdings Corporation, Leica Biosystems, Vector Laboratories, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., GenScript Biotech

Global Immunohistochemistry (IHC) Market Trends and Insights

Major companies operating in the immunohistochemistry (IHC) market are focusing on advancing diagnostic accuracy through innovative technologies and high-quality reagents to enhance the effectiveness of tissue analysis in various clinical and research applications. The Neoflex multiomics mass spectrometry imaging (MSI) system is an advanced imaging platform designed for precise tissue analysis, enabling researchers to transition from discovery to clinical applications through high-resolution mass spectrometry techniques, particularly for spatially mapping biomolecules in tissues. For instance, in June 2024, Bruker Corporation, a US-based company that develops and manufactures scientific instruments and analytical and diagnostic solutions, launched its matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) Neoflex Imaging Profiler for mass spectrometry-based tissue imaging. The Neoflex multiomics mass spectrometry imaging (MSI) system addresses the need to advance from discovery imaging to clinical tissue research. It features Bruker's 10-kHz smartbeam 3D laser, enhanced imaging detectors, and supports OME-TIFF file output with SCiLS Scope software.

What Are Latest Mergers And Acquisitions In The Immunohistochemistry (IHC) Market?

In December 2023, Danaher Corporation, a US-based life sciences & diagnostics company, acquired Abcam plc for an undisclosed amount. With this acquisition, Danaher aimed to expand its life science reagents and consumables platform, enhance its protein tool capabilities for research and diagnostics, accelerate growth in the life sciences ecosystem, and bolster its global reach in supplying integrated solutions to researchers and clinicians. Abcam plc is a UK-based biotechnology company that specializes in providing antibodies, reagents, assays and immunohistochemistry (IHC).

Regional Outlook

North America was the largest region in the immunohistochemistry (IHC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Immunohistochemistry (IHC) Market?

The immunohistochemistry (IHC) market consists of sales of primary antibodies, slide staining system, tissue microarrays, tissue processing systems, slide scanners secondary antibodies, histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents and stabilizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.